As the treatment landscape in patients with non‐small cell lung cancer (NSCLC) harboring mutations in the epidermal growth factor receptor (EGFRm) continues to evolve, real‐world health utility scores (HUS) become increasingly important for economic analyses. The gene discussed is EGFR; the disease is lung cancer.